Understanding the association between clinical staging accuracy, treatment response, and survival among gastric cancer patients through Bayesian analysis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35819061/
doi: 10.1002/jso.27016. Online ahead of print. 1 Department of Medicine, Epidemiology, and Population Sciences, Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas, USA. 2 Department of...
Conclusions: NAT is associated with improved survival for GC, but it seems to be contingent on treatment response among patients with intermediate-stage disease.
Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II Studies - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35267477/
Studies JVDB and JVCZ examined alternative ramucirumab dosing regimens as monotherapy or combined with paclitaxel, respectively, in patients with advanced/metastatic gastric/gastroesophageal junction (GEJ) adenocarcinoma. For JVDB, randomized patients ( N...
Conclusion: The lack of a dose/exposure-response relationship in these studies supports the standard dose of ramucirumab 8 mg/kg-Q2W as monotherapy or in combination with paclitaxel as second-line treatment for advanced/metastatic gastric/GEJ adenocarcinoma.
Successful conversion surgery for stage IV gastric cancer with liver metastases after second-line chemotherapy with ramucirumab and paclitaxel: a case report - Surgical Case Reports
Source : https://surgicalcasereports.springeropen.com/articles/10.1186/s40792-022-01412-x
Background In recent years, conversion surgery after chemotherapy has been considered a promising strategy for improving the prognosis of patients with stage IV gastric cancer. However, there are few reports...
Conclusions: Conversion surgery might be clinically useful for improving survival in certain patients with gastric cancer, including those who previously received second-line chemotherapy.
A phase II multicenter trial assessing the efficacy and safety of first-line S-1 + ramucirumab in elderly patients with advanced/recurrent gastric cancer: KSCC1701 - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35349925/
doi: 10.1016/j.ejca.2022.02.028. 1 Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan. 2 Department of Medical Oncology, Toranomon Hospital, Tokyo, Japan. Electronic address: [email protected]. 3 Division of...
Conclusion: Considering these findings, S-1 ramucirumab appears to be an excellent treatment option for elderly patients with ARGC.
SOCRATE-PRODIGE 55 trial: A randomized phase II study to evaluate second-line ramucirumab alone or with paclitaxel in older patients with advanced gastric cancer - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35351371/
1 Service des Maladies de l'Appareil Digestif, INSERM U1242, CHU de Rennes, CHU Pontchaillou, Université de Rennes 1, Rennes Cedex9 35033, France. 2 Service d'Oncologie, Center Antoine Lacassagne, Nice, France....
Perspectives: As older patients are at higher risk of chemotherapy toxicity, ramucirumab alone could be an interesting alternative to Paclitaxel plus ramucirumab, as a second-line therapy for patients ≥ 70 years old with advanced GC, and needs to be evaluated.